Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AIQUY vs LIN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LIN Overall Winner 6-Pillar Tally: AIQUY 0 – 6 LIN Matrix Metrics: AIQUY 1 – 9 LIN

As of Nov 16, 2026, Linde plc Ordinary Share (LIN) is the stronger overall head-to-head candidate over AIQUY (AIQUY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AIQUY carries a Unified Composite Score of 36.5/100 (SELL) at $42.56 (N/M Forward P/E, N/A operating margin), whereas LIN carries 39.3/100 (SELL) at $526.29 (28.9x Forward P/E, 27.6% operating margin).

  • Defensive Composite Rating Caution: Although LIN compares more favorably head-to-head, both AIQUY (36.5/100 SELL) and LIN (39.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AIQUY vs LIN
AIQUY US Equity
AIQUY
Institutional Equity
$42.56
+0.02% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 18% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 5.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 73
RSI-14: 73.0 · SMA20: $40.60 · SMA50: $39.21
LIN NASDAQ Head-to-Head Winner
Linde plc Ordinary Share
Industrial Inorganic Chemicals
$526.29
+0.04% 1D
Market Cap $239.9B
TTM Revenue $36.2B
Forward P/E 28.9x
Beta / 30D Vol 0.01β · 17% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 32.0 Fund 36.0 Flow 52.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 66
RSI-14: 66.1 · SMA20: $515.09 · SMA50: $491.22

6-Pillar Scorecard Institutional Category Breakdown (AIQUY 0 – 6 LIN)

Columns: Metric · AIQUY · LIN
1. Valuation Multiples LIN
Forward P/E N/M 28.9x
Trailing P/E N/M 34.7x
PEG Ratio N/M 2.07x
EV / Revenue N/M 7.2x
2. Growth & Scale LIN
Revenue Growth (YoY) N/A +9.2%
Earnings Growth (YoY) N/A -10.5%
TTM Revenue (USD) N/A $36.2B
Market Cap N/A $239.9B
3. Profitability & Quality LIN
Gross Margin N/A 47.9%
Operating Margin N/A 27.6%
Net Profit Margin N/A 19.3%
Return on Equity (ROE) N/A 17.7%
4. Balance Sheet & Cash Flow LIN
Cash Generation (TTM) N/A $5.08B
Cash Flow Margin N/A 14.0%
Net Cash / Leverage N/A ROE $22.8B Net Debt (0.68x D/E)
Dividend Yield None (0.00%) 1.20%
5. Options & Positioning LIN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 20.5% (45th %ile)
Put/Call OI Skew N/A 1.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat LIN
OpEx & R&D Intensity N/A 20.3% of Rev ($7.36B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Specialty Chemicals Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AIQUY (1) vs LIN (9)
Institutional Metric AIQUY LIN Criterion Row Edge
Market Capitalization
Scale
N/A $239.9B Larger Scale LIN
Trailing P/E Ratio
Valuation
N/M 34.7x Lower Multiple LIN
Forward P/E Ratio
Valuation
N/M 28.9x Lower Multiple LIN
Revenue Growth (YoY)
Growth
N/A +9.2% Higher Growth LIN
Operating Margin (TTM)
Profitability
N/A 27.6% Higher Margin LIN
Net Profit Margin
Profitability
N/A 19.3% Higher Margin LIN
Return on Equity (ROE)
Capital Efficiency
N/A 17.7% Higher ROE LIN
52-Week Range Position
Momentum
96% ($33–$43) 86% ($388–$548) Stronger Trend AIQUY
Beta / 30D Volatility
Risk Regime
0.32β · 18% Vol 0.01β · 17% Vol Lower Realized Risk LIN
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 39.3 / 100 (SELL) Higher Composite LIN
Trailing 12M Revenue (USD)
Operating Scale
N/A $36.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 47.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.07x PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $5.08B ($22.8B Net Debt (0.68x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AIQUY +3.12 pp
AIQUY: +9.78% · LIN: +6.66%
3M Horizon LIN +0.65 pp
AIQUY: +10.26% · LIN: +10.91%
6M Horizon AIQUY +13.04 pp
AIQUY: +16.98% · LIN: +3.94%
1Y Horizon LIN +6.24 pp
AIQUY: +16.49% · LIN: +22.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AIQUY vs LIN. Trailing 12-month operating profitability (AIQUY N/A vs LIN 27.6%) and valuation multiples (AIQUY N/M vs LIN 28.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AIQUY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LIN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$36.2B
Gross Margin47.9%
Op. Margin27.6%
ROE / Fwd P/E17.7% · 28.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AIQUY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIQUY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.5%
IV Percentile 45th %ile
Put/Call OI Skew 1.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AIQUY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LIN Moat Profile Scale & Operating Efficiency Moat
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $239.9B market capitalization and 27.6% operating margin.
OpEx & R&D Reinvestment 20.3% of Rev ($7.36B)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (15 partners):
Exxon Mobil Corporation Chevron Corporation BASF SE Dow Inc.

Investor FAQ AIQUY vs LIN Key Questions & Quantitative Answers

As of Nov 16, 2026, Linde plc Ordinary Share (LIN) is the stronger overall head-to-head candidate over AIQUY (AIQUY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AIQUY carries a Unified Composite Score of 36.5/100 (SELL) at $42.56 (N/M Forward P/E, N/A operating margin), whereas LIN carries 39.3/100 (SELL) at $526.29 (28.9x Forward P/E, 27.6% operating margin). Defensive Composite Rating Caution: Although LIN compares more favorably head-to-head, both AIQUY (36.5/100 SELL) and LIN (39.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

LIN leads the Growth & Scale pillar: AIQUY posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LIN at +9.2% YoY revenue growth and -10.5% YoY earnings growth on $36.2B TTM revenue (47.9% gross margin, 27.6% operating margin). On trailing 12-month operating scale, AIQUY generates N/A in USD-normalized revenue versus $36.2B for LIN. In operating R&D and SG&A reinvestment, AIQUY deploys N/A (0 90-day corporate R&D disclosures) versus 20.3% of Rev ($7.36B) (0 disclosures) for LIN.

LIN screens cheaper on headline valuation multiples. AIQUY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LIN trades at 28.9x Forward P/E, 34.7x Trailing P/E, 2.07x PEG, and 7.2x EV/Revenue (14.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AIQUY (N/A ROE) versus LIN (17.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AIQUY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 18% Vol realized risk). By comparison, LIN carries 20.5% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 1.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 17% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.